Dimensional Fund Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Dimensional Fund Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-343,215	Closed	-$16.5M	–	3412
2020 Q1	$16.5M	Hold	343,215	–	–	0.01%	1867
2019 Q4	$16.1M	Sell	343,215 -4,024	-1%	-$178K	0.01%	2150
2019 Q3	$8.21M	Sell	347,239 -9,615	-3%	-$285K	﹤0.01%	2432
2019 Q2	$10.7M	Sell	356,854 -17,219	-5%	-$394K	﹤0.01%	2368
2019 Q1	$8.38M	Sell	374,073 -32,047	-8%	-$689K	﹤0.01%	2470
2018 Q4	$7.39M	Buy	406,120 +11,941	+3%	+$187K	﹤0.01%	2466
2018 Q3	$7.13M	Buy	394,179 +179,600	+84%	+$2.13M	﹤0.01%	2563
2018 Q2	$2.13M	Buy	214,579 +46,126	+27%	+$318K	﹤0.01%	2873
2018 Q1	$894K	Buy	168,453 +124,750	+285%	+$892K	﹤0.01%	3020
2017 Q4	$371K	Buy	+43,703	New	+$537K	﹤0.01%	3134

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Dimensional Fund Advisors's RARX Position: Q2 2020 in Review

Dimensional Fund Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 343,215 shares — an estimated $16.5M sold.

Dimensional Fund Advisors first reported a position in RARX in Q4 2017 and held it in 10 quarters. The position peaked at $16.5M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Dimensional Fund Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Dimensional Fund Advisors sold 343,215 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $16.5M.
Dimensional Fund Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 10 quarters.
Dimensional Fund Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $16.5M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Dimensional Fund Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.